For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
14
views
52
references
 Top references
cited by
72
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      118
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Chinese consensus guidelines for diagnosis and management of gastrointestinal stromal tumor

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          In order to further promote the standardization of diagnosis and treatment of gastrointestinal stromal tumor (GIST) in China, the members of Chinese Society of Clinical Oncology (CSCO) Expert Committee on GIST thoroughly discussed the key contents of the consensus guidelines, and voted on the controversial issue. In final, the Chinese consensus guidelines for the diagnosis and management of GIST (2017 edition) was formed on the basis of 2013 edition consensus guidelines, which is hereby announced. The consensus included the pathological diagnosis, recurrence risk classification evaluation, targeted agent therapy, surgery and principles of surveillance of GIST.

          Related collections

          Most cited references52

          • Record: found
          • Abstract: found
          • Article: not found

          Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.

          Ronald DeMatteo, Karla V. Ballman, Cristina R Antonescu … (2009)
          Gastrointestinal stromal tumour is the most common sarcoma of the intestinal tract. Imatinib mesylate is a small molecule that inhibits activation of the KIT and platelet-derived growth factor receptor alpha proteins, and is effective in first-line treatment of metastatic gastrointestinal stromal tumour. We postulated that adjuvant treatment with imatinib would improve recurrence-free survival compared with placebo after resection of localised, primary gastrointestinal stromal tumour. We undertook a randomised phase III, double-blind, placebo-controlled, multicentre trial. Eligible patients had complete gross resection of a primary gastrointestinal stromal tumour at least 3 cm in size and positive for the KIT protein by immunohistochemistry. Patients were randomly assigned, by a stratified biased coin design, to imatinib 400 mg (n=359) or to placebo (n=354) daily for 1 year after surgical resection. Patients and investigators were blinded to the treatment group. Patients assigned to placebo were eligible to crossover to imatinib treatment in the event of tumour recurrence. The primary endpoint was recurrence-free survival, and analysis was by intention to treat. Accrual was stopped early because the trial results crossed the interim analysis efficacy boundary for recurrence-free survival. This study is registered with ClinicalTrials.gov, number NCT00041197. All randomised patients were included in the analysis. At median follow-up of 19.7 months (minimum-maximum 0-56.4), 30 (8%) patients in the imatinib group and 70 (20%) in the placebo group had had tumour recurrence or had died. Imatinib significantly improved recurrence-free survival compared with placebo (98% [95% CI 96-100] vs 83% [78-88] at 1 year; hazard ratio [HR] 0.35 [0.22-0.53]; one-sided p<0.0001). Adjuvant imatinib was well tolerated, with the most common serious events being dermatitis (11 [3%] vs 0), abdominal pain (12 [3%] vs six [1%]), and diarrhoea (ten [2%] vs five [1%]) in the imatinib group and hyperglycaemia (two [<1%] vs seven [2%]) in the placebo group. Adjuvant imatinib therapy is safe and seems to improve recurrence-free survival compared with placebo after the resection of primary gastrointestinal stromal tumour. US National Institutes of Health and Novartis Pharmaceuticals.
          Article 0 comments Cited 305 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.

            George Demetri, Margaret von Mehren, Cristina R Antonescu … (2010)
            The standard of care for managing patients with gastrointestinal stromal tumors (GISTs) rapidly changed after the introduction of effective molecularly targeted therapies involving tyrosine kinase inhibitors (TKIs), such as imatinib mesylate and sunitinib malate. A better understanding of the molecular characteristics of GISTs have improved the diagnostic accuracy and led to the discovery of novel immunomarkers and new mechanisms of resistance to TKI therapy, which in turn have resulted in the development of novel treatment strategies. To address these issues, the NCCN organized a task force consisting of a multidisciplinary panel of experts in the fields of medical oncology, surgical oncology, molecular diagnostics, and pathology to discuss the recent advances, identify areas of future research, and recommend an optimal approach to care for patients with GIST at all stages of disease. The task force met for the first time in October 2003 and again in December 2006 and October 2009. This supplement describes the recent developments in the field of GIST as discussed at the October 2009 meeting.
            Article 0 comments Cited 268 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.

              Michael Heinrich, Robert G Maki, Christopher L Corless … (2008)
              Most gastrointestinal stromal tumors (GISTs) harbor mutant KIT or platelet-derived growth factor receptor alpha (PDGFRA) kinases, which are imatinib targets. Sunitinib, which targets KIT, PDGFRs, and several other kinases, has demonstrated efficacy in patients with GIST after they experience imatinib failure. We evaluated the impact of primary and secondary kinase genotype on sunitinib activity. Tumor responses were assessed radiologically in a phase I/II trial of sunitinib in 97 patients with metastatic, imatinib-resistant/intolerant GIST. KIT/PDGFRA mutational status was determined for 78 patients by using tumor specimens obtained before and after prior imatinib therapy. Kinase mutants were biochemically profiled for sunitinib and imatinib sensitivity. Clinical benefit (partial response or stable disease for > or = 6 months) with sunitinib was observed for the three most common primary GIST genotypes: KIT exon 9 (58%), KIT exon 11 (34%), and wild-type KIT/PDGFRA (56%). Progression-free survival (PFS) was significantly longer for patients with primary KIT exon 9 mutations (P = .0005) or with a wild-type genotype (P = .0356) than for those with KIT exon 11 mutations. The same pattern was observed for overall survival (OS). PFS and OS were longer for patients with secondary KIT exon 13 or 14 mutations (which involve the KIT-adenosine triphosphate binding pocket) than for those with exon 17 or 18 mutations (which involve the KIT activation loop). Biochemical profiling studies confirmed the clinical results. The clinical activity of sunitinib after imatinib failure is significantly influenced by both primary and secondary mutations in the predominant pathogenic kinases, which has implications for optimization of the treatment of patients with GIST.
              Article 0 comments Cited 207 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Contributors
                Hui Cao
                Lin Shen
                Journal
                Journal ID (nlm-ta): Chin J Cancer Res
                Journal ID (iso-abbrev): Chin. J. Cancer Res
                Journal ID (publisher-id): CJCR
                Title: Chinese Journal of Cancer Research
                Publisher: AME Publishing Company
                ISSN (Print): 1000-9604
                ISSN (Electronic): 1993-0631
                Publication date (Print): August 2017
                Volume: 29
                Issue: 4
                Pages: 281-293
                Affiliations
                [1 ] Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China
                [2 ] Peking University People’s Hospital, Department of Gastrointestinal Surgery, Beijing 100044, China
                [3 ] Fudan University Zhongshan Hospital, Department of Pathology, Shanghai 200032, China
                [4 ] Sichuang University Huaxi Hospital, Department of Gastrointestinal Surgery, Chengdu 610041, China
                [5 ] People’s Liberation Army Cancer Center, 81st Hospital of People’s Liberation Army, Department of Medical Oncology, Nanjing 210002, China
                [6 ] Fudan University Cancer Hospital, Department of Gastric Surgery, Shanghai 200032, China
                [7 ] The First Affiliated Hospital, Sun Yat-sen University, Department of Gastrointestinal Surgery, Guangzhou 510080, China
                [8 ] Shanxi Provincial Cancer Hospital, Department of Gastrointestinal Surgery, Shanxi 030013, China
                [9 ] Chinese PLA General Hospital, Department of General Surgery, Beijing 100853, China
                [10 ] Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Department of General Surgery, Shanghai 200127, China
                Author notes
                Article
                Publisher ID: cjcr-29-4-lijian
                DOI: 10.21147/j.issn.1000-9604.2017.04.01
                PMC ID: 5592117
                PubMed ID: 28947860
                SO-VID: 9e4e26bc-e88f-4cfe-bd50-dd0db0893a4c
                Copyright © Copyright © 2017 Chinese Journal of Cancer Research. All rights reserved.
                License:

                This work is licensed under a Creative Commons Attribution-Non Commercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/

                History
                Date received : 19 July 2017
                Date accepted : 13 August 2017
                Categories
                Subject: Guidelines

                Keywords: gastrointestinal stromal tumor,diagnosis,therapy,consensus
                Data availability:
                Keywords: gastrointestinal stromal tumor, diagnosis, therapy, consensus

                Comments

                Comment on this article

                scite_

                Similar content118

                See all similar

                Cited by72

                See all cited by

                Most referenced authors969

                See all reference authors